Advaxis, Inc. announced that Gregory Mayes, Executive Vice President and Chief Operating Officer, has been elected to the Company's Board of Directors. Mr. Mayes joined Advaxis in October 2013, bringing with him more than 20 years of management experience in the pharmaceutical industry. Mr. Mayes has been key to identifying and negotiating partnerships with the AdvaxisLm Technology™ including clinical collaborations with MedImmune and Merck.

In addition, Mr. Mayes has helped cultivate growing base of institutional shareholders. Prior to Advaxis, Mr. Mayes held executive leadership positions with ImClone Systems, Eli Lilly and AstraZeneca Pharmaceuticals. While at ImClone, he was selected to lead the integration of ImClone with Eli Lilly and also supported the clinical development and commercialization of ERBITUX® (cetuximab).

While with Astra Zeneca, Mr. Mayes provided legal support for the development and commercialization of five approved oncology products.